DRUG REACTIONS

MARKET NEWS

Drug news from the US The orphan drug epoprostenol ['Flolan'; Glaxo

Well come] has been launched for long-term IV treatment of primary pulmonary hypertension in the US.)

The product was approved last September for treating patients with class III and class IV primary pulmonary hypertension, which is a rare disorder that affects approximately 500 people in the US.

LHRH analogues TAP Holding's 'Lupron Depot' [Ieuprorelin;

leuprolide acetate] and Zeneca's 'Zoladex' [goserelin] are new depot formulations of luteinising hormone-releasing hormone (LHRH) analogues that have been approved in the US as palliative therapies for advanced prostate cancer.2

The extended release formulations deliver leuprorelin 22.5mg or goserelin 1O.8mg over a period of 3 months. Both agents have previously been available as monthly depot formulations.

1 •... product launches/approvals: Glaxo Wellcome launches F10lan in U.S. Scrip 2099: 23, 2 Feb 19962, us approval for Zoladex & Lupron depot. Scrip: 22, No. 2099, 2 Feb 1996 800J1492.4

0156-2703/9611023-000211$01 .00° Adie International Limited '996, All rights reserved

21

INPHARMA'",O Feb 1996